Resverlogix is a scientific presenter, not an exhibitor, as American Diabetes Association 2017 meeting. I posted this a few weeks back.

Looks like the Resverlogix team is presenting a poster on June 11, 2017 at American Diabetes Association 2017, but the title is nearly the same as the same titles/abstracts presented earlier this year at ACC and EAS. The ADA title (abstract embargoed until early June) is "Apabetalone (RVX-208) Lowers Major Adverse Cardiovascular Events (MACE) in CVD Patients with Diabetes Mellitus by Affecting Complement Pathway and Microbiome Activity."